118 related articles for article (PubMed ID: 12111990)
21. Genistein alters growth factor signaling in transgenic prostate model (TRAMP).
Wang J; Eltoum IE; Lamartiniere CA
Mol Cell Endocrinol; 2004 Apr; 219(1-2):171-80. PubMed ID: 15149738
[TBL] [Abstract][Full Text] [Related]
22. Nuclear matrix proteins in well and poorly differentiated human breast cancer cell lines.
Samuel SK; Minish TM; Davie JR
J Cell Biochem; 1997 Jul; 66(1):9-15. PubMed ID: 9215523
[TBL] [Abstract][Full Text] [Related]
23. Application of the transgenic adenocarcinoma mouse prostate (TRAMP) model for pre-clinical therapeutic studies.
Martiniello-Wilks R; Dane A; Mortensen E; Jeyakumar G; Wang XY; Russell PJ
Anticancer Res; 2003; 23(3B):2633-42. PubMed ID: 12894551
[TBL] [Abstract][Full Text] [Related]
24. Evidence for downregulation of calcium signaling proteins in advanced mouse adenocarcinoma.
Ruddat VC; Whitman S; Klein RD; Fischer SM; Holman TR
Prostate; 2005 Jul; 64(2):128-38. PubMed ID: 15666362
[TBL] [Abstract][Full Text] [Related]
25. Disruption of arginase II alters prostate tumor formation in TRAMP mice.
Mumenthaler SM; Rozengurt N; Livesay JC; Sabaghian A; Cederbaum SD; Grody WW
Prostate; 2008 Oct; 68(14):1561-9. PubMed ID: 18663728
[TBL] [Abstract][Full Text] [Related]
26. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
27. Prostate targeting: PSP94 gene promoter/enhancer region directed prostate tissue-specific expression in a transgenic mouse prostate cancer model.
Gabril MY; Onita T; Ji PG; Sakai H; Chan FL; Koropatnick J; Chin JL; Moussa M; Xuan JW
Gene Ther; 2002 Dec; 9(23):1589-99. PubMed ID: 12424611
[TBL] [Abstract][Full Text] [Related]
28. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model.
Kaplan-Lefko PJ; Chen TM; Ittmann MM; Barrios RJ; Ayala GE; Huss WJ; Maddison LA; Foster BA; Greenberg NM
Prostate; 2003 May; 55(3):219-37. PubMed ID: 12692788
[TBL] [Abstract][Full Text] [Related]
29. HMGA2 expression in a canine model of prostate cancer.
Winkler S; Murua Escobar H; Meyer B; Simon D; Eberle N; Baumgartner W; Loeschke S; Nolte I; Bullerdiek J
Cancer Genet Cytogenet; 2007 Sep; 177(2):98-102. PubMed ID: 17854662
[TBL] [Abstract][Full Text] [Related]
30. Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization.
Degl'Innocenti E; Grioni M; Boni A; Camporeale A; Bertilaccio MT; Freschi M; Monno A; Arcelloni C; Greenberg NM; Bellone M
Eur J Immunol; 2005 Jan; 35(1):66-75. PubMed ID: 15597325
[TBL] [Abstract][Full Text] [Related]
31. Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer.
Adhami VM; Siddiqui IA; Ahmad N; Gupta S; Mukhtar H
Cancer Res; 2004 Dec; 64(23):8715-22. PubMed ID: 15574782
[TBL] [Abstract][Full Text] [Related]
32. Expression of the F-box protein SKP2 induces hyperplasia, dysplasia, and low-grade carcinoma in the mouse prostate.
Shim EH; Johnson L; Noh HL; Kim YJ; Sun H; Zeiss C; Zhang H
Cancer Res; 2003 Apr; 63(7):1583-8. PubMed ID: 12670908
[TBL] [Abstract][Full Text] [Related]
33. Transgenic mouse with human mutant p53 expression in the prostate epithelium.
Elgavish A; Wood PA; Pinkert CA; Eltoum IE; Cartee T; Wilbanks J; Mentor-Marcel R; Tian L; Scroggins SE
Prostate; 2004 Sep; 61(1):26-34. PubMed ID: 15287091
[TBL] [Abstract][Full Text] [Related]
34. Genomic instability-based transgenic models of prostate cancer.
Voelkel-Johnson C; Voeks DJ; Greenberg NM; Barrios R; Maggouta F; Kurtz DT; Schwartz DA; Keller GM; Papenbrock T; Clawson GA; Norris JS
Carcinogenesis; 2000 Aug; 21(8):1623-7. PubMed ID: 10910968
[TBL] [Abstract][Full Text] [Related]
35. Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.
Morgenbesser SD; McLaren RP; Richards B; Zhang M; Akmaev VR; Winter SF; Mineva ND; Kaplan-Lefko PJ; Foster BA; Cook BP; Dufault MR; Cao X; Wang CJ; Teicher BA; Klinger KW; Greenberg NM; Madden SL
Prostate; 2007 Jan; 67(1):83-106. PubMed ID: 17013881
[TBL] [Abstract][Full Text] [Related]
36. Novel syngeneic pseudo-orthotopic prostate cancer model: vascular, mitotic and apoptotic responses to castration.
Frost GI; Lustgarten J; Dudouet B; Nyberg L; Hartley-Asp B; Borgström P
Microvasc Res; 2005 Jan; 69(1-2):1-9. PubMed ID: 15797254
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical evaluation of PCNA, p53, HSP60, HSP10 and MUC-2 presence and expression in prostate carcinogenesis.
Cappello F; Rappa F; David S; Anzalone R; Zummo G
Anticancer Res; 2003; 23(2B):1325-31. PubMed ID: 12820390
[TBL] [Abstract][Full Text] [Related]
38. Suppressive effects of antiandrogens, finasteride and flutamide on development of prostatic lesions in a transgenic rat model.
Cho YM; Takahashi S; Asamoto M; Suzuki S; Tang M; Shirai T
Prostate Cancer Prostatic Dis; 2007; 10(4):378-83. PubMed ID: 17457304
[TBL] [Abstract][Full Text] [Related]
39. Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model.
Pflug BR; Pecher SM; Brink AW; Nelson JB; Foster BA
Prostate; 2003 Nov; 57(3):245-54. PubMed ID: 14518031
[TBL] [Abstract][Full Text] [Related]
40. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity.
Garcia-Hernandez Mde L; Gray A; Hubby B; Klinger OJ; Kast WM
Cancer Res; 2008 Feb; 68(3):861-9. PubMed ID: 18245488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
